Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis

Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis

Abstract Background Dipeptidyl peptidase 4 (DPP4) is a serine exopeptidase able to inactivate various oligopeptides, and also a hepatokine. Hepatocyte-specific overexpression of DPP4 is associated with hepatic insulin resistance and liver steatosis. Method We examined whether weekly DPP4 inhibitor o...

Full description

Bibliographic Details
Main Authors: Sachiko Hattori, Kazuomi Nomoto, Tomohiko Suzuki, Seishu Hayashi
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Diabetology & Metabolic Syndrome
Subjects:
NAFLD/NASH
Omarigliptin
Dipeptidyl peptidase 4
Online Access:https://doi.org/10.1186/s13098-021-00644-5

Internet

https://doi.org/10.1186/s13098-021-00644-5

Similar Items